BridgeBio Oncology Therapeutics, Inc. (BBOT)
Nasdaq · Healthcare · Biotechnology
$3.60−7.46%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $289M
- 52-week range
- $3.58 – $14.87
- 52-week change
- −68.14%
- EPS (trailing)
- −$0.07
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$134M
- Diluted EPS
- −$4.30
- Free cash flow
- −$115M
From the company’s annual report on SEC EDGAR.
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Headquarters: South San Francisco, United States · 88 employees · bbotx.com